Stay updated on Pembrolizumab Plus Entinostat in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Plus Entinostat in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab Plus Entinostat in Melanoma Clinical Trial page
- CheckyesterdayChange DetectedThe web page has been updated from version v2.16.2 to v2.16.3.SummaryDifference0.0%
- Check8 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check15 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.8%
- Check22 days agoNo Change Detected
- Check44 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check58 days agoChange DetectedThe webpage has been updated to include new information about a study on melanoma, specifically mentioning the involvement of Syndax Pharmaceuticals and the principal investigator, Stergios Moschos, MD. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference61%
- Check65 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
Stay in the know with updates to Pembrolizumab Plus Entinostat in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Plus Entinostat in Melanoma Clinical Trial page.